BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35040284)

  • 21. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
    Nielsen SM; De Simone LM; Olopade OI
    J Genet Couns; 2018 Dec; 27(6):1405-1410. PubMed ID: 29946849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
    Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.
    Díaz-Velásquez CE; Gitler R; Antoniano A; Kershenovich Sefchovich R; De La Cruz-Montoya AH; Martínez-Gregorio H; Rojas-Jiménez EA; Cortez Cardoso Penha R; Terrazas LI; Wegman-Ostrosky T; Levi-Lahad E; Zabaleta J; Perdomo S; Vaca-Paniagua F
    Front Genet; 2023; 14():1094260. PubMed ID: 36845387
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
    Ndugga-Kabuye MK; Issaka RB
    Fam Cancer; 2019 Oct; 18(4):465-469. PubMed ID: 31531760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas.
    Soewito S; Wyatt R; Berenson E; Poullard N; Gessay S; Mette L; Marin E; Shelby K; Alvarez E; Choi BY; Aviles C; Pulido-Saldivar AM; Otto PM; Jatoi I; Ramamurthy C; Ignatius M; Kaklamani VG; Tomlinson GE
    JCO Oncol Pract; 2022 May; 18(5):e805-e813. PubMed ID: 35544645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
    Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
    JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
    Bernstein-Molho R; Galmor L; Laitman Y; Segev S; Friedman E
    Cancer; 2021 Oct; 127(19):3599-3604. PubMed ID: 34157778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
    Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
    Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
    Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
    Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
    Mutat Res; 2023; 827():111831. PubMed ID: 37453313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
    Vidal AF; Ferraz RS; El-Husny A; Silva CS; Vinasco-Sandoval T; Magalhães L; Raiol-Moraes M; Barra WF; Pereira CLBL; de Assumpção PP; de Brito LM; Vialle RA; Santos S; Ribeiro-Dos-Santos Â; Ribeiro-Dos-Santos AM
    BMC Cancer; 2021 Apr; 21(1):363. PubMed ID: 33827469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
    Caswell-Jin JL; Gupta T; Hall E; Petrovchich IM; Mills MA; Kingham KE; Koff R; Chun NM; Levonian P; Lebensohn AP; Ford JM; Kurian AW
    Genet Med; 2018 Feb; 20(2):234-239. PubMed ID: 28749474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.